GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe<sup>6</sup>-Gln<sup>7</sup>-Trp<sup>8</sup>...

Full description

Saved in:
Bibliographic Details
Main Authors: Karim Obeid (Author), Panagiotis Kanellopoulos (Author), Ayman Abouzayed (Author), Adam Mattsson (Author), Vladimir Tolmachev (Author), Berthold A. Nock (Author), Theodosia Maina (Author), Anna Orlova (Author)
Format: Book
Published: MDPI AG, 2024-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_76e700bb020b4623bb32b8e8e73fddd6
042 |a dc 
100 1 0 |a Karim Obeid  |e author 
700 1 0 |a Panagiotis Kanellopoulos  |e author 
700 1 0 |a Ayman Abouzayed  |e author 
700 1 0 |a Adam Mattsson  |e author 
700 1 0 |a Vladimir Tolmachev  |e author 
700 1 0 |a Berthold A. Nock  |e author 
700 1 0 |a Theodosia Maina  |e author 
700 1 0 |a Anna Orlova  |e author 
245 0 0 |a GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics 
260 |b MDPI AG,   |c 2024-04-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics16040513 
500 |a 1999-4923 
520 |a Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe<sup>6</sup>-Gln<sup>7</sup>-Trp<sup>8</sup>-Ala<sup>9</sup>-Val<sup>10</sup>-Gly<sup>11</sup>-His<sup>12</sup>-Sta<sup>13</sup>-Leu<sup>14</sup>-NH<sub>2</sub>) analogs, such as [<sup>111</sup>In]In-DOTAGA-PEG2-RM26. We recently showed that its Gly<sup>11</sup>/Sar<sup>11</sup>-substituted version, [<sup>111</sup>In]In-AU-RM26-M1, resisted degradation by neprilysin (NEP) while in circulation and achieved higher tumor uptake in mice. We herein introduce the following three new AU-RM26-M1 mimics labeled with In-111, with basic residues in the linker: (i) AU-RM26-M2 (PEG2-Pip), (ii) AU-RM26-M3 (PEG2-Arg), and (iii) AU-RM26-M4 (Arg-Arg-Pip). These analogs were compared in PC-3 cells and animal models vs. AU-RM26-M1 (reference). The new analogs showed high affinity and specificity for the GRPR, exhibiting an uptake and distribution pattern in PC-3 cells typical for a radiolabeled GRPR-antagonist. They showed high stability in peripheral mice blood, except for [<sup>111</sup>In]In-AU-RM26-M3. AU-RM26-M4 achieved the highest tumor uptake and promising background clearance, followed by [<sup>111</sup>In]In-RM26-M2, showing lower background levels. These findings were confirmed for [<sup>111</sup>In]In-AU-RM26-M2 and [<sup>111</sup>In]In-AU-RM26-M4 by micro-SPECT/CT at 4 and 24 h post-injection. Hence, the type of positively charged residues in the linker of AU-RM26-M1 mimics strongly influenced biological behavior. The analogs with Pip next to DPhe<sup>6</sup> demonstrated the best overall characteristics and warrant further investigation. 
546 |a EN 
690 |a prostate cancer 
690 |a GRPR 
690 |a GRPR-antagonist 
690 |a radiotheranostics 
690 |a PC-3 cell/tumor 
690 |a neprilysin 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 16, Iss 4, p 513 (2024) 
787 0 |n https://www.mdpi.com/1999-4923/16/4/513 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/76e700bb020b4623bb32b8e8e73fddd6  |z Connect to this object online.